Skip to main content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

2006 | OriginalPaper | Hoofdstuk

Is er iets op tegen om een sulfonylureumderivaat, metformine én thiazolidinedionen tegelijk te gebruiken?

Auteurs : A.F.E. Bots, Dr. K.J. Gorter

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Diabetes mellitus type 2 is een chronisch progressieve ziekte, die wordt gekenmerkt door duurzaam verhoogde glucosespiegels ten gevolge van verminderde insulineproductie (β-cel disfunctie) en een verminderde insulinegevoeligheid in lever, skeletspier en vetweefsel, waardoor meer insuline nodig is voor opname van glucose in het weefsel en voor de remming van de gluconeogenese (1).
Literatuur
go back to reference DeFronzo RA. Pharmalogical therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303. DeFronzo RA. Pharmalogical therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
go back to reference Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
go back to reference Inzucchi SE. Oral Antihyperglycemic Therapy for Type 2 Diabetes. JAMA 2002; 287: 360-72. Inzucchi SE. Oral Antihyperglycemic Therapy for Type 2 Diabetes. JAMA 2002; 287: 360-72.
go back to reference Zimmerman B.R. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-21. Zimmerman B.R. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-21.
go back to reference Hundal R.S, Krssak M, Dufour S, et al. Mechanism by with metformine reduces glucose production in type 2 diabetes. Diabetes 2000; 49:2063-69. Hundal R.S, Krssak M, Dufour S, et al. Mechanism by with metformine reduces glucose production in type 2 diabetes. Diabetes 2000; 49:2063-69.
go back to reference Dailey III GE, Noor M.A, Park JS, Bruce S, Fiedorek FT. Glycemic Control with Glyburide/Metformin Tablets in Combination with Rosiglitazone in Patients with Type 2 Diabetes: A Randomized, Double-Blind Trial. Am J Med 2004; 116: 223-29. Dailey III GE, Noor M.A, Park JS, Bruce S, Fiedorek FT. Glycemic Control with Glyburide/Metformin Tablets in Combination with Rosiglitazone in Patients with Type 2 Diabetes: A Randomized, Double-Blind Trial. Am J Med 2004; 116: 223-29.
go back to reference Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin and a Thiazolidinedione: Results of a 30-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Clinical Therapeutics 2005; 27: 1535-47. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin and a Thiazolidinedione: Results of a 30-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Clinical Therapeutics 2005; 27: 1535-47.
go back to reference Aljabri K, Kozak SE, Thompson DM. Addition of Pioglitazone or Bedtime Insulin to Maximal Doses of Sulfonylurea and Metformin in Type 2 diabetes Patients with Poor Glucose Control: A Prospective, Randomised Trial. Am J Med 2004; 116: 230-35. Aljabri K, Kozak SE, Thompson DM. Addition of Pioglitazone or Bedtime Insulin to Maximal Doses of Sulfonylurea and Metformin in Type 2 diabetes Patients with Poor Glucose Control: A Prospective, Randomised Trial. Am J Med 2004; 116: 230-35.
go back to reference Rosenstock J, Sugimoto D, Strange P, Stewart J.A, Soltes-Rak E, Dailey G. Triple Therapy in Type 2 Diabetes. Diabetes Care 2006; 29:554-59. Rosenstock J, Sugimoto D, Strange P, Stewart J.A, Soltes-Rak E, Dailey G. Triple Therapy in Type 2 Diabetes. Diabetes Care 2006; 29:554-59.
go back to reference Orbay E, Sargin M, Sargin H, Gözü H, et al. Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes. Endocrine Jounal 2004; 51: 521-27. Orbay E, Sargin M, Sargin H, Gözü H, et al. Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes. Endocrine Jounal 2004; 51: 521-27.
go back to reference Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med 2006; 260 (2): 125-33. Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med 2006; 260 (2): 125-33.
go back to reference Rosak C, Standl E, Reblin T, Stammer H, Seidel DK. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimes during daily practice in patients with type 2 diabetes. Int.J.Clin Prac 2006; 60 (9): 1040-47. Rosak C, Standl E, Reblin T, Stammer H, Seidel DK. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimes during daily practice in patients with type 2 diabetes. Int.J.Clin Prac 2006; 60 (9): 1040-47.
go back to reference Kahn SE, Haffner SM, et al., for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 2006; 355: 2427-43. Kahn SE, Haffner SM, et al., for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 2006; 355: 2427-43.
go back to reference Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
go back to reference Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
go back to reference Rutten GEHM, Grauw WJC de, Nijpels G, Goudswaard AN, Uitewaal PIM, Does FEE van der, Heine RI, Ballegooie E van, Verduijn MM, Bouma M. Standaard Diabetes Mellitus type 2. Huisarts Wet 2006; 49 (3): 137-52. Rutten GEHM, Grauw WJC de, Nijpels G, Goudswaard AN, Uitewaal PIM, Does FEE van der, Heine RI, Ballegooie E van, Verduijn MM, Bouma M. Standaard Diabetes Mellitus type 2. Huisarts Wet 2006; 49 (3): 137-52.
Metagegevens
Titel
Is er iets op tegen om een sulfonylureumderivaat, metformine én thiazolidinedionen tegelijk te gebruiken?
Auteurs
A.F.E. Bots
Dr. K.J. Gorter
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_389